SEPN
What one share of Septerna holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (“GPCR”) oral small molecule drug discovery powered by our proprietary Native Complex Platform®.
Septerna’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.21 |
|---|---|
| Profit | −$0.54 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | $2.35 |
| Cash and investments | $11.31 |
| Book value | $8.47 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.07 | $0.29 | $1.32 | −$19.11 | — | −$12.11 |
| 2024 | $0.11 | −$7.26 | $0.21 | −$7.03 | — | — |
| 2025 | $1.04 | −$1.10 | $0.01 | $2.48 | — | $8.52 |